Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence | Synapse
April 8, 2026
Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
Key Points
This article reviews the role of TL1A inhibitors in treating inflammatory bowel disease (IBD) and discusses their mechanisms of action.
Literature review of existing studies on TL1A inhibitors and their effects on IBD
Analysis of the inflammation-fibrosis continuum related to IBD therapies
TL1A-DR3 interaction contributes to mucosal immunity and stromal injury
Inhibiting TL1A presents a novel strategy to enhance IBD treatment effectiveness
Potential to surpass current therapeutic limitations in IBD management
Abstract
TL1A-DR3 integrates mucosal immunity with stromal injury, positioning inhibitors as a novel class to overcome IBD therapeutic ceilings by targeting the inflammation-fibrosis continuum.